Loading...
The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201
Banerjee, S. N. Van Nieuwenhuysen, E. Aghajanian, C. D'Hondt, V. Monk, B. J. Clamp, A. Prendergast, E. Oaknin, A. Ring, K. Colombo, N.
Banerjee, S. N.
Van Nieuwenhuysen, E.
Aghajanian, C.
D'Hondt, V.
Monk, B. J.
Clamp, A.
Prendergast, E.
Oaknin, A.
Ring, K.
Colombo, N.
Abstract
Authors
Banerjee, S. N.
Van Nieuwenhuysen, E.
Aghajanian, C.
D'Hondt, V.
Monk, B. J.
Clamp, A.
Prendergast, E.
Oaknin, A.
Ring, K.
Colombo, N.
Holloway, R. W.
Rodrigues, M.
Chon, H. S.
Gourley, C.
Santin, A. D.
Thaker, P. H.
Gennigens, C.
Newman, G.
Salinas, E.
Youssoufian, H.
Moore, K. N.
Lustgarten, S.
O'Malley, D. M.
Van Gorp, T.
Grisham, R. N.
Van Nieuwenhuysen, E.
Aghajanian, C.
D'Hondt, V.
Monk, B. J.
Clamp, A.
Prendergast, E.
Oaknin, A.
Ring, K.
Colombo, N.
Holloway, R. W.
Rodrigues, M.
Chon, H. S.
Gourley, C.
Santin, A. D.
Thaker, P. H.
Gennigens, C.
Newman, G.
Salinas, E.
Youssoufian, H.
Moore, K. N.
Lustgarten, S.
O'Malley, D. M.
Van Gorp, T.
Grisham, R. N.
Description
Date
2025
Publisher
Collections
Files
Loading...
Found from Unpaywall
Adobe PDF, 1.75 MB
Keywords
Type
Article
Citation
Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, D'Hondt V, Monk BJ, Clamp A, et al. The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201. Future Oncology. 2025 DEC 20;21(30):3859-71.